Skip to Content

From Fungus To Patient: Building A Psychedelic Supply Chain From The Ground Up.

Havn Life Sciences

How Havn Life Sciences intends to fill the psilocybin supply chain gap

HAVN LIFE SCIENCES (CSE:HAVN | FSE:5NP)

Havn Life Sciences (CSE:HAVN | FSE:5NP) is a Biotechnology company specializing in solving the psilocybin supply chain problem of delivering naturally-derived psilocybin directly to the researchers that need it. In early September, Havn Life went public by listing on the Canadian Securities Exchange.

RECOGNISING THE BENEFITS OF PSILOCYBIN

Coinciding with the rise in open dialogue about mental health issues and the importance of recognising it’s OK not to be OK, psychedelics are recognized for the role they could play in helping solve this desperate and devastating situation. Research into the benefits of psilocybin directly from plants dates back to the 1950s. When psychedelics were deemed a Schedule I drug in the following decade, this halted research efforts and stunted progress. It’s now recognized that unlocking the positive and potentially life-changing properties of the drug psilocybin has never been more important.

There is promising activity going on in the psychedelics sector, and Havn Life (CSE:HAVN | FSE:5NP) is excited to see others entering this new business ecosystem. This company’s unique selling point is in its drive to establish a supply chain to facilitate the research supply chain to patients.

Many of the existing studies and treatments are being carried out using synthetic psilocybin. This is effective and commendable, but it’s not what many patients are looking for. Many of those suffering from treatment resistant depression, PTSD and advanced mental health deterioration have struggled with pharmaceuticals and would much prefer a natural plant or mushroom-based alternative.

This is where Havn Life (CSE:HAVN | FSE:5NP) will excel. Through its subsidiary Havn Labs, it is constructing a GMP-compliant lab and has begun the complex application process to cut through the regulatory red-tape and supply researchers with the natural ingredients they desire. This state-of-the-art lab will soon host its multidisciplinary research team, which will be busy working on life-enhancing solutions.

CULTIVATING ITS AREAS OF EXPERTISE

Despite the benefits of psilocybin being increasingly recognized in many aspects of improving life, there is no infrastructure in place to legally extract and supply psilocybin directly from the mushroom. This is a gaping hole in the psychedelics market and is providing the impetus to drive Havn Life (CSE:HAVN | FSE:5NP) forward in rectifying this.

Havn Life (CSE:HAVN | FSE:5NP) has two divisions; Labs and Retail. Havn Labs division will focus on research and development and solving this supply chain problem. Havn Retail will sell natural health products directly to consumers, namely products in the form of novel compounds derived from legal medicinal mushroom varieties including Reishi, Cordyceps and Lion’s Mane. These products could potentially help optimize the human body through enhancing immunity, improving cognitive function and achieving desirable sleep patterns.


SPECIAL REPORT DOWNLOAD – DISCOVER HOW HAVN LIFE SCIENCES IS FULLY FUNDED FOR A 12-MONTH ACTION PLAN.


The two paths to market

Havn Life (CSE:HAVN | FSE:5NP) is following two paths to market. One route focuses on natural health products and the beneficial effects of medicinal mushrooms. The company’s scientists conduct this through its Havn Retail division and will be selling natural health products directly to consumers or, as a white label product, to contract manufacturers. This has potential to generate cash quickly and consistently.

Havn Life’s second route to market will take longer as it requires regulatory approval for the growth of magic mushrooms, psychedelic extraction and supply. The firm will then supply these compounds to academic research facilities once a Controlled Drugs and Substances Dealer’s Licence for Psilocybin and Psilocin is received. Alternatively, Havn Life’s (CSE:HAVN | FSE:5NP) scientists will use their naturally grown supply to formulate microdosing therapies for use in pre-clinical trials. This is a very exciting area to be involved in and Havn Life (CSE:HAVN | FSE:5NP) has the potential to become a leading operator in this space.

Microdosing is when psilocybin is cut into minute portions to avoid psychedelic hallucinations, but to capture the performance enhancing abilities present in its natural state. In recent years this has gained recognition for its ability to improve creativity, cognitive function and memory, as well as enhancing energy.

By focussing on the importance of the natural ingredients, Havn Life Sciences (CSE:HAVN | FSE:5NP) has recognized a key feature missing from the existing psychedelics sector. Building a strong foundation and taking the initiative to carry out the groundwork necessary for future expansion and development is sure to set Havn Life (CSE:HAVN | FSE:5NP) up as a leading and vital force in the psilocybin market supply chain.

Its dedicated lab is due to begin operating early next year with the intention to build a unique library of magic-mushroom derived compounds ready for use in clinical research studies and trials. Havn Life (CSE:HAVN | FSE:5NP) hopes this will be ready to generate profits within two years.


DOWNLOAD OUR SPECIAL REPORT ON HAVN LIFE’S GROUNDBREAKING PROGRESS IN THE PSILOCYBIN SPACE!


Tapping into accelerating growth in a projected US$34.3 billion market!

HAVN LIFE SCIENCES (CSE:HAVN | FSE:5NP)

EVOLVING WITH CONFIDENCE

In conjunction with the legalisation of cannabis in many states, the demand for quality psilocybin has skyrocketed. But unlike cannabis, it faces a bigger struggle towards legalisation. Thankfully, progress is being made and new trials are being given regulatory approval. Compass Pathways (Nasdaq:CMPS), is a $1.4bn psilocybin company that recently floated on the Nasdaq stock exchange. In January it was granted a US patent covering use of its psilocybin formulation in addressing treatment-resistant depression.

Havn Life (CSE:HAVN | FSE:5NP) has applied for a Controlled Drugs and Substances Dealer’s Licence for Psilocybin and Psilocin, which it expects to be in place early next year.

In the meantime, the company recently received its first Health Canada license, which has allowed it to begin the development of methods for safe and standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. Mushroom.

This will ensure it has already advanced in its journey when its dealer’s license arrives. The license will allow it to supply research institutes with the standardized psilocybin that they require.

Havn Life (CSE:HAVN | FSE:5NP) founders and Co-CEO’s Tim Moore and Susan Chapelle learned from witnessing start-ups crash in the Cannabis sector that many businesses won’t make it if they don’t have the right setup from the start.

Scientific expertise is important, but equally so is a business development plan and a leadership team confident in their ability to see the company from newcomer to long-established success. This is their aim for Havn Life (CSE:HAVN | FSE:5NP), and to ensure their success they’ve put an impressive team together.

“ONE OF THE LESSONS THAT WE BRING FROM THE CANNABIS INDUSTRY IS THAT MANY FAILED TO ASSEMBLE AN OPERATIONS TEAM, RELYING FAR TOO HEAVILY ON PROMOTERS AND GROWERS.

SO, IN ADDITION TO OUR SCIENTIFIC TEAM, WE HAVE PEOPLE THAT HAVE ACTUALLY RUN BUSINESSES IN AREAS SIMILAR TO PSYCHEDELICS. THEY CAN BUILD A BRAND, RUN A FACTORY, NAVIGATE REGULATION AND POLICY, MANAGE SUPPLY CHAINS, RECRUIT RETAILERS AND RAISE CAPITAL. THIS IS HOW YOU CREATE A BUSINESS THAT WORKS.”

Tim Moore, Co-CEO, Havn Life Sciences

REVENUE STREAMS

While the long-term growth prospects for Havn Life Sciences (CSE:HAVN | FSE:5NP) are exponential, R&D and regulatory hurdles require patience. This means revenue from the lab division will take time, but this is where Havn Retail comes into its own. The retail side of the business is based on legal health and wellness products that can potentially enhance and optimize life, but without barriers to distribution. Havn Life (CSE:HAVN | FSE:5NP) expects revenue from this side of the business to be forthcoming as soon as Q1 2021. Despite being legal and readily available, this is a sector expected to be worth US$34.3 billion globally by 2024.

Havn Life’s (CSE:HAVN | FSE:5NP) Chief Psychedelic Officer Ivan Casselman is developing a series of novel compounds from everyday legal mushroom varieties like Reishi and Cordyceps that could potentially help reduce inflammation, ease stress & anxiety, lift mood and enhance creativity. Casselman has a Ph.D. in Plant Science and a Master’s in Ethnobotany and is well versed in the strengthening world of psychedelics.

Havn Life’s (CSE:HAVN | FSE:5NP) overall goal is to make life fulfilling for those suffering and to get there it plans to expand its distribution channels into 2022 and beyond. This is a very exciting sector to be investing in, and Havn Life Sciences (CSE:HAVN | FSE:5NP) offers early investors the chance to own a part of a company with unbounded growth opportunity.

With Covid-19 causing mental health and depression cases to multiply, this burgeoning health problem is only going to intensify. This will rapidly raise the need for studies into treating mental health problems and in-depth research into the magical powers of the unassuming mushroom. Early investors will enjoy being a part of the exciting journey to success. This essentially makes shareholders a co-owner in a business that has the potential to earn income both from its consumers and an untold number of research labs, all the while, on a mission to enhance lives and improve wellbeing.


SPECIAL REPORT DOWNLOAD – DISCOVER HOW HAVN LIFE SCIENCES IS FULLY FUNDED FOR A 12-MONTH ACTION PLAN.


IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Havn Life Sciences Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and sixty six thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

Related Articles

Headlines

teathers app screenshot

App Empowering Private Investors

Crowd Equity for Placings, IPOs and Live Market Blockbuilds, designed to give provate investors access to placements and Intial Public Offerings (IPOs), predominantly on the London Stock Exchange’s Alternative Investment Market (AIM).